Procurement for neutralising antibodies
DHSC invites suppliers to provide information on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARS-CoV-2 variants, supply availability for 2021-2022 and future years and plans for regulatory approval in the UK, if not yet approved.
Buyer
Department of Health and Social Care
Value
£1
Published
22 Sept 2021
Closes
22 Sept 2021
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Not provided
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 Procurement for neutralising antibodies
Value not provided
The Department is interested in engaging with the emerging market prior to the publication of a contract notice to find innovative neutralising antibody COVID-19 therapies that could inform the specification of requirements, conditions of contract and commercial model. Further details of how suppliers may engage with the Department are included in section VI...
Delivery: Westminster
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.